Clinical Trial

Description of the Immune Response to Yellow Fever Vaccination

Study acronym: IVORY2
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 29, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years. The project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-04.
Trial Details
NCT Number NCT06718127
Lead Sponsor Institut Pasteur
Conditions Immunization, Infections
Enrollment 38 participants
Start Date 2024-09-30
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-29